Sanofi continues to morph its R&D footprint in an effort to become more focused, nimble and innovative. As reported in Fierce Biotech, Sanofi will sell two R&D sites to CRO partner Covance in a 10 year, $2.2 B pact. Covance will assume ownership of Sanofi's Porcheville, France and Alnwick, UK sites at a price of $25 M. Sanofi will handle an important part of Sanofi's development pipeline.
"A key strategy for Sanofi-Aventis is to transform its R&D model and discover new medicines through the use of novel technologies and innovative partnerships," declared Sanofi R&D chief Marc Cluzel. Covance also anounced the continuation and expansion of a similar deal with Eli Lilly today (see Outsourcing Pharma.com).
For Sanofi, this is a continuation of a flurry of activity that it has engaged in this year to reshape its R&D model. Other deals (in no particular order) announced this year include:
- A new R&D center is being built in China to support development of cures for diseases more common to that area (here)
- Sanofi will join the Massachuesetts Life Science Center to expand its partnering and licensing activies (here)
- Sanofi and Aviesan - essentially a consortium of universities and private institutes in France - formed a research pact to develop therapies in focused disease areas (here)
- Last week the purchase of VaxDesign and its novel, rapid in vitro screening methodology to help select the best preclinical candidates to enter the pipeline (here)
It looks like they're serious and have really gotten busy in the past year and it's not over yet. We still have a potential Genzyme acquisition looming on the horizon.
Posted by Bruce Lehr September 30th 2010.